Alexis Guédon: Cancer-Associated Upper-Extremity Deep Vein Thrombosis
Alexis Guédon, Junior Deputy Editor at the European Journal of Preventive Cardiology, shared on LinkedIn about a recent article he and his colleagues co-authored, published in JACC Journals, adding:
“Upper-extremity deep vein thrombosis in cancer is sometimes viewed primarily as a catheter-related complication with a relatively low risk of recurrence.
In JACC Journals: CardioOncology, we report findings from 5,195 patients enrolled in the international RIETE registry, including 2,210 with active cancer.
We found that:
- Cancer was associated with higher risks of recurrent venous thromboembolism and bleeding.
- Risk differed substantially by cancer site: lung cancer had the highest recurrence risk, whereas genitourinary cancers had the highest bleeding risk.
- After anticoagulation discontinuation, the 2-year recurrence risk reached 17.2% in patients with lung cancer.
- Longer anticoagulation was associated with a lower risk of recurrence after treatment discontinuation, although these observational association should not be interpreted as causal.
These results suggest that cancer-associated upper-extremity deep vein thrombosis is more than a mechanical catheter-related complication.
Tumor biology appears to influence the balance between thrombosis and bleeding, supporting careful reassessment before anticoagulation is discontinued.
A study led by Olivier Espitia and Manuel Monreal, with the RIETE Investigators.”
Title: Upper Extremity Deep Vein Thrombosis in Cancer Patients: Clinical Course by Cancer Site
Authors: Olivier Espitia, Alexis F. Guedon, Emma Courouve, Benjamin Brenner, Juan José López-Núñez, Romain Chopard, Alicia Lorenzo, Patricia Sigüenza, Son Truong Nguye

Stay updated on all scientific advances with Hemostasis Today.
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials
-
Aug 13, 2026, 16:16Isabella Presch: A New AI Approach to Protein Engineering